Rep. Kevin Hern Sells Kenvue Inc. (NYSE:KVUE) Stock

Posted by Defense World Staff on Apr 7th, 2026

Representative Kevin Hern (Republican-Oklahoma) recently sold shares of Kenvue Inc. (NYSE:KVUE). In a filing disclosed on April 03rd, the Representative disclosed that they had sold between $15,001 and $50,000 in Kenvue stock on March 17th. The trade occurred in the Representative’s “HERN FAMILY REVOCABLE TRUST” account.

Representative Kevin Hern also recently made the following trade(s):

Sold $1,001 – $15,000 in shares of Exact Sciences (NASDAQ:EXAS) on 3/24/2026.
Sold $50,001 – $100,000 in shares of Prologis (NYSE:PLD) on 3/20/2026.
Sold $15,001 – $50,000 in shares of T. Rowe Price Group (NASDAQ:TROW) on 3/20/2026.
Sold $15,001 – $50,000 in shares of Medtronic (NYSE:MDT) on 3/20/2026.
Sold $500,001 – $1,000,000 in shares of Texas Instruments (NASDAQ:TXN) on 3/18/2026.
Sold $500,001 – $1,000,000 in shares of Smartstop Self Storage REIT (NYSE:SMA) on 3/18/2026.
Sold $50,001 – $100,000 in shares of BlackRock MuniAssets Fund (NYSE:MUA) on 3/17/2026.
Sold $15,001 – $50,000 in shares of Cognizant Technology Solutions (NASDAQ:CTSH) on 3/17/2026.
Sold $15,001 – $50,000 in shares of Invesco (NYSE:IVZ) on 3/17/2026.
Sold $15,001 – $50,000 in shares of Becton, Dickinson and Company (NYSE:BDX) on 3/17/2026.

Kenvue Stock Up 0.9%

KVUE stock opened at $17.30 on Tuesday. The stock has a market capitalization of $33.15 billion, a P/E ratio of 22.46, a price-to-earnings-growth ratio of 3.89 and a beta of 0.61. The company has a current ratio of 0.96, a quick ratio of 0.68 and a debt-to-equity ratio of 0.66. Kenvue Inc. has a 12 month low of $14.02 and a 12 month high of $25.17. The firm has a 50-day moving average price of $17.98 and a 200-day moving average price of $17.07.

Kenvue (NYSE:KVUE – Get Free Report) last posted its earnings results on Tuesday, February 17th. The company reported $0.27 EPS for the quarter, topping analysts’ consensus estimates of $0.22 by $0.05. The firm had revenue of $3.78 billion during the quarter, compared to analysts’ expectations of $3.68 billion. Kenvue had a net margin of 9.72% and a return on equity of 19.72%. The business’s revenue for the quarter was up 3.2% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.26 earnings per share. As a group, equities research analysts anticipate that Kenvue Inc. will post 1.14 EPS for the current fiscal year.

Kenvue Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Wednesday, February 25th. Stockholders of record on Wednesday, February 11th were issued a $0.2075 dividend. The ex-dividend date of this dividend was Wednesday, February 11th. This represents a $0.83 dividend on an annualized basis and a dividend yield of 4.8%. Kenvue’s dividend payout ratio is 107.79%.

Wall Street Analysts Forecast Growth

A number of research firms have recently commented on KVUE. Jefferies Financial Group cut shares of Kenvue from a “buy” rating to a “hold” rating and dropped their target price for the stock from $23.00 to $18.00 in a report on Friday, January 30th. Canaccord Genuity Group increased their target price on shares of Kenvue from $17.00 to $18.00 and gave the stock a “hold” rating in a report on Wednesday, February 18th. Weiss Ratings reiterated a “hold (c-)” rating on shares of Kenvue in a research report on Friday, January 9th. Argus raised shares of Kenvue to a “hold” rating in a report on Friday, March 6th. Finally, UBS Group upped their price target on shares of Kenvue from $17.00 to $19.00 and gave the company a “neutral” rating in a research report on Wednesday, February 18th. Three equities research analysts have rated the stock with a Buy rating and thirteen have given a Hold rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $19.58.

Read Our Latest Report on Kenvue

Institutional Trading of Kenvue

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Hsbc Holdings PLC increased its holdings in Kenvue by 31.8% in the fourth quarter. Hsbc Holdings PLC now owns 5,106,368 shares of the company’s stock valued at $88,231,000 after purchasing an additional 1,230,957 shares during the period. Stance Capital LLC increased its holdings in Kenvue by 14.1% in the fourth quarter. Stance Capital LLC now owns 80,721 shares of the company’s stock valued at $1,392,000 after purchasing an additional 9,961 shares during the period. World Investment Advisors increased its holdings in Kenvue by 60.9% in the fourth quarter. World Investment Advisors now owns 19,670 shares of the company’s stock valued at $339,000 after purchasing an additional 7,444 shares during the period. Advisortrust Partners LLC acquired a new stake in Kenvue in the fourth quarter valued at $325,000. Finally, Reflection Asset Management acquired a new stake in Kenvue during the 4th quarter valued at approximately $32,000. 97.64% of the stock is currently owned by institutional investors and hedge funds.

About Representative Hern

Kevin Hern (Republican Party) is a member of the U.S. House, representing Oklahoma’s 1st Congressional District. He assumed office on November 13, 2018. His current term ends on January 3, 2027.

Hern (Republican Party) is running for re-election to the U.S. House to represent Oklahoma’s 1st Congressional District. He declared candidacy for the 2026 election.

Kevin Hern went into business as a McDonald’s franchisee in 1999. He acquired 10 McDonald’s franchises by 2012. He served on the McDonald’s National Leadership Team for 13 years, including the tax policy team, the insurance corporation, and as chairman of the economics team. From 2011 to 2015, he was chairman of the finance committee of the Oklahoma Turnpike Authority.

About Kenvue

(Get Free Report)

Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over‑the‑counter medicines.

The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.